News|Articles|June 19, 2024
Insights on Evolving Treatment Strategies for Multiple Myeloma
The panel provides key takeaways on the most impactful innovations shaping the future of multiple myeloma treatment.
Advertisement
Episodes in this series
Advertisement
Related to this article
Beth Faiman, PhD, and Sikander Ailawadhi, MD, discuss clinical trials and nursing impacts of on-body isatuximab delivery in multiple myeloma.
Beth Faiman, PhD, and Sikander Ailawadhi, MD, discuss clinical trials and nursing impacts of on-body isatuximab delivery in multiple myeloma.
Stephanie Sorrentino, BSN, OCN, discusses operational strategies, toxicity management, and patient education in frontline multiple myeloma care.
The FDA has approved oral iberdomide (Zenbexus) for relapsed/refractory multiple myeloma, offering patients a highly potent, accessible therapy.
FDA approves lirafugratinib (Lyrfigtu) for FGFR2+ cholangiocarcinoma. Review REFOCUS trial data, 70 mg daily dosing, and nursing safety guidelines.
Yesne Alici, MD, of Memorial Sloan Kettering Cancer Center discusses key delirium screening, patient capacity, and bioethics in oncology nursing care.
A nurse-led support program significantly reduces death anxiety in women with breast cancer on hormonal therapy, study finds.
FDA approves lutetium lu 177 dotatate (Bravnetsa) as bioequivalent to Lutathera for GEP-NETs. Review key nursing takeaways and safety guidelines.
Advertisement
Advertisement
Trending on Oncology Nursing News
1
FDA Approves Lirafugratinib for Advanced FGFR2+ Cholangiocarcinoma
2
FDA Approves Lutetium Lu 177 Dotatate for GEP-NET Care
3
Nurse-Led Support Reduces Death Anxiety in Breast Cancer Care
4
How On-Body Treatment Delivery Reduces Nursing Burden in Myeloma Care
5